

Smith Cie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8094389/publications.pdf>

Version: 2024-02-01

136
papers

8,796
citations

134610

34
h-index

53065

89
g-index

140
all docs

140
docs citations

140
times ranked

12145
citing authors

#	ARTICLE	IF	CITATIONS
1	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. <i>Leukemia</i> , 2022, 36, 476-481.	3.3	25
2	Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101658.	3.9	28
3	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	2.2	19
4	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. <i>Molecular Medicine</i> , 2022, 28, 20.	1.9	18
5	Clinical measurement of cellular DNA damage hypersensitivity in patients with DNA repair defects. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 50.	1.2	0
6	Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides. <i>Communications Biology</i> , 2022, 5, 185.	2.0	7
7	Elevated CD21 ^{low} B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 716-727.	2.0	13
8	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13153.	1.3	5
9	2'-O ² -(N ⁶ -(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity. <i>Nucleic Acid Therapeutics</i> , 2022, , .	2.0	4
10	Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. <i>Journal of Clinical Immunology</i> , 2022, 42, 1130-1136.	2.0	13
11	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. <i>Molecular Medicine</i> , 2022, 28, 54.	1.9	18
12	Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	21
13	Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare. <i>IScience</i> , 2022, 25, 104698.	1.9	15
14	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. <i>Pharmaceutics</i> , 2021, 13, 116.	2.0	5
15	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. <i>Leukemia</i> , 2021, 35, 1317-1329.	3.3	35
16	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630942.	1.8	119
17	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2021, 5, e564.	1.2	15
18	Resistance Mutations to BTK Inhibitors Originate From the NF- κ B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. <i>Frontiers in Immunology</i> , 2021, 12, 689472.	2.2	32

#	ARTICLE	IF	CITATIONS
19	Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo. <i>Biomedicines</i> , 2021, 9, 1046.	1.4	6
20	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	267
21	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 443-456.	2.0	4
22	Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. <i>Nature Biomedical Engineering</i> , 2021, 5, 1084-1098.	11.6	41
23	Editorial: New Insights on Brutonâ€™s Tyrosine Kinase Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 804735.	2.2	1
24	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. <i>EBioMedicine</i> , 2021, 74, 103705.	2.7	161
25	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells. <i>Cancers</i> , 2020, 12, 1143.	1.7	7
26	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. <i>Blood Advances</i> , 2020, 4, 2439-2450.	2.5	15
27	Chemical Development of Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019, 2036, 3-16.	0.4	14
28	Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1568-1577.	2.0	40
29	Precursor B-cell development in bone marrow of Good syndrome patients. <i>Clinical Immunology</i> , 2019, 200, 39-42.	1.4	14
30	Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. <i>Neurotherapeutics</i> , 2019, 16, 248-262.	2.1	18
31	Oligonucleotide Binding to Non-B-DNA in MYC. <i>Molecules</i> , 2019, 24, 1000.	1.7	5
32	Oligonucleotideâ€™Palladacycle Conjugates as Splice-Correcting Agents. <i>Molecules</i> , 2019, 24, 1180.	1.7	10
33	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. <i>PLoS ONE</i> , 2019, 14, e0211651.	1.1	7
34	Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6. <i>Blood Advances</i> , 2019, 3, 2722-2731.	2.5	10
35	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019, 11, 666.	2.0	10
36	Therapeutic Oligonucleotides: State of the Art. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 605-630.	4.2	208

#	ARTICLE	IF	CITATIONS
37	Kappa Δ -deleting recombination excision circle levels remain low or undetectable throughout life in patients with X Δ -linked agammaglobulinemia. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 453-456.	1.1	6
38	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 749-752.	1.0	8
39	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 132, 29-40.	2.0	17
40	Ibrutinib induces rapid down Δ -regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia Δ -related genes in blood and lymph nodes. <i>British Journal of Haematology</i> , 2018, 183, 212-224.	1.2	13
41	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. <i>ACS Omega</i> , 2017, 2, 2165-2177.	1.6	9
42	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. <i>Nucleic Acids Research</i> , 2017, 45, 5153-5169.	6.5	19
43	Specific dsDNA recognition by a mimic of the DNA binding domain of the c-Myc/Max transcription factor. <i>Chemical Communications</i> , 2017, 53, 6653-6656.	2.2	14
44	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. <i>Scientific Reports</i> , 2017, 7, 11043.	1.6	28
45	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). <i>Seminars in Cancer Biology</i> , 2017, 45, 36-49.	4.3	11
46	ANKRD54 preferentially selects Bruton Δ -Tyrosine Kinase (BTK) from a Human Src-Homology 3 (SH3) domain library. <i>PLoS ONE</i> , 2017, 12, e0174909.	1.1	2
47	B Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA Processing. <i>PLoS ONE</i> , 2016, 11, e0160255.	1.1	33
48	Disruption of Higher Order DNA Structures in Friedreich Δ -Ataxia (GAA) Δ Repeats by PNA or LNA Targeting. <i>PLoS ONE</i> , 2016, 11, e0165788.	1.1	18
49	Wnt/ Δ ² -Catenin Stimulation and Laminins Support Cardiovascular Cell Progenitor Expansion from Human Fetal Cardiac Mesenchymal Stromal Cells. <i>Stem Cell Reports</i> , 2016, 6, 607-617.	2.3	20
50	Cells release subpopulations of exosomes with distinct molecular and biological properties. <i>Scientific Reports</i> , 2016, 6, 22519.	1.6	728
51	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 381-391.	2.0	12
52	Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e290.	2.3	17
53	Next-generation bis-locked nucleic acids with stacking linker and 2 Δ -glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. <i>Nucleic Acids Research</i> , 2016, 44, 2007-2019.	6.5	24
54	Clickable trimethylguanosine cap analogs modified within the triphosphate bridge: synthesis, conjugation to RNA and susceptibility to degradation. <i>RSC Advances</i> , 2016, 6, 8317-8328.	1.7	9

#	ARTICLE	IF	CITATIONS
55	A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells. <i>Leukemia and Lymphoma</i> , 2016, 57, 183-192.	0.6	1
56	Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26316.	5.5	1,077
57	Characterization of All Possible Single-Nucleotide Change Caused Amino Acid Substitutions in the Kinase Domain of Bruton Tyrosine Kinase. <i>Human Mutation</i> , 2015, 36, 638-647.	1.1	39
58	Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides. <i>Nucleic Acid Therapeutics</i> , 2015, 25, 65-77.	2.0	18
59	Oligonucleotide Therapies: The Past and the Present. <i>Human Gene Therapy</i> , 2015, 26, 475-485.	1.4	220
60	Cyclodextrin-peptide conjugates for sequence specific DNA binding. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5273-5278.	1.5	14
61	Sequence-selective DNA recognition and enhanced cellular up-take by peptide-steroid conjugates. <i>Chemical Communications</i> , 2015, 51, 17552-17555.	2.2	8
62	Safety and efficacy of DNA vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1306-1308.	1.4	45
63	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e172.	2.3	3
64	Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e140.	2.3	28
65	Btk29A Promotes Wnt4 Signaling in the Niche to Terminate Germ Cell Proliferation in <i>Drosophila</i> . <i>Science</i> , 2014, 343, 294-297.	6.0	45
66	Design and Application of Bispecific Splice-Switching Oligonucleotides. <i>Nucleic Acid Therapeutics</i> , 2014, 24, 13-24.	2.0	5
67	Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. <i>Journal of Clinical Investigation</i> , 2014, 124, 4067-4081.	3.9	39
68	Diagnostics of Primary Immunodeficiency Diseases: A Sequencing Capture Approach. <i>PLoS ONE</i> , 2014, 9, e114901.	1.1	73
69	Synthesis and evaluation of stability of m3G-CAP analogues in serum-supplemented medium and cytosolic extract. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7921-7928.	1.4	10
70	Biological Activity and Biotechnological Aspects of Locked Nucleic Acids. <i>Advances in Genetics</i> , 2013, 82, 47-107.	0.8	82
71	Agammaglobulinemia: causative mutations and their implications for novel therapies. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1205-1221.	1.3	26
72	Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. <i>Nucleic Acids Research</i> , 2013, 41, 3257-3273.	6.5	25

#	ARTICLE	IF	CITATIONS
91	Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. <i>International Journal of Cancer</i> , 2005, 117, 418-430.	2.3	36
92	Inducible H1 Promoter-Driven Lentiviral siRNA Expression by Stuffer Reporter Deletion. <i>Oligonucleotides</i> , 2005, 15, 139-144.	2.7	15
93	Functional replacement of <i>Drosophila</i> Btk29A with human Btk in male genital development and survival. <i>FEBS Letters</i> , 2005, 579, 4131-4137.	1.3	19
94	Cooperative strand invasion of supercoiled plasmid DNA by mixed linear PNA and PNA-peptide chimeras. <i>New Biotechnology</i> , 2004, 21, 51-59.	2.7	21
95	Gene therapy of monogenic and cardiovascular disorders. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 941-949.	1.4	6
96	The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. <i>BioEssays</i> , 2001, 23, 436-446.	1.2	266
97	Proximal promoter of the murine syndecan-1 gene is not sufficient for the developmental pattern of syndecan expression in B lineage cells. <i>American Journal of Hematology</i> , 2001, 67, 20-26.	2.0	5
98	Microphthalmia, facial anomalies, microcephaly, thumb and hallux hypoplasia, and agammaglobulinemia. <i>American Journal of Medical Genetics Part A</i> , 2001, 101, 209-212.	2.4	14
99	In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. <i>Gene Therapy</i> , 2001, 8, 84-87.	2.3	57
100	BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones. <i>Journal of Gene Medicine</i> , 2000, 2, 204-209.	1.4	18
101	The cellular phenotype conditions Btk for cell survival or apoptosis signaling. <i>Immunological Reviews</i> , 2000, 178, 49-63.	2.8	32
102	A peptide nucleic acid nuclear localization signal fusion that mediates nuclear transport of DNA. <i>Nature Biotechnology</i> , 1999, 17, 784-787.	9.4	386
103	Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. <i>Gene Therapy</i> , 1999, 6, 12-21.	2.3	161
104	Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. , 1999, 13, 280-285.		91
105	Intercellular spread of GFP-VP22. <i>Journal of Gene Medicine</i> , 1999, 1, 275-279.	1.4	47
106	Intercellular spread of GFP-VP22. , 1999, 1, 275.		2
107	Thermal unfolding of small proteins with SH3 domain folding pattern. , 1998, 31, 309-319.		51
108	X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase. <i>Seminars in Immunopathology</i> , 1998, 19, 369-381.	4.0	23

#	ARTICLE	IF	CITATIONS
109	An Academic Centre for Gene Therapy Research with Clinical Grade Manufacturing Capability. <i>Annals of Medicine</i> , 1997, 29, 579-583.	1.5	5
110	Suicide genes and bystander killing: local and distant effects. <i>Gene Therapy</i> , 1997, 4, 273-274.	2.3	22
111	Direct and sequential switching from $\hat{I}^1/4$ to \hat{E} in patients with <i>Schistosoma mansoni</i> infection and atopic dermatitis. <i>European Journal of Immunology</i> , 1997, 27, 130-135.	1.6	20
112	B cell-deficient $\hat{I}^1/4$ MT mice as an experimental model for <i>Mycoplasma</i> infections in X-linked agammaglobulinemia. <i>European Journal of Immunology</i> , 1997, 27, 2118-2121.	1.6	17
113	Registries of immunodeficiency patients and mutations. , 1997, 10, 261-267.		8
114	Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. , 1997, 71, 624-629.		44
115	X-Linked Agammaglobulinemia A Clinical and Molecular Analysis. <i>Medicine (United States)</i> , 1996, 75, 287-299.	0.4	222
116	<i>Bcl-2</i> rearrangements with breakpoints in both <i>vcr</i> and <i>mbr</i> in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 92, 647-652.	1.2	22
117	X-linked agammaglobulinemia (XLA): A genetic tyrosine kinase (<i>Btk</i>) disease. <i>BioEssays</i> , 1996, 18, 825-834.	1.2	66
118	Characterization of <i>Haemophilus influenzae</i> Isolates from the Respiratory Tract of Patients with Primary Antibody Deficiencies: Evidence for Persistent Colonizations. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 303-313.	1.5	25
119	Retroviral-Mediated Gene Transfer of CD34-Enriched Bone Marrow and Peripheral Blood Cells During Autologous Stem Cell Transplantation for Multiple Myeloma. Huddinge Hospital and Karolinska Institute, Huddinge, Sweden. <i>Human Gene Therapy</i> , 1994, 5, 1279-1286.	1.4	17
120	X-Linked Agammaglobulinemia and Other Immunoglobulin Deficiencies. <i>Immunological Reviews</i> , 1994, 138, 159-183.	2.8	120
121	T-cell receptor \hat{I}^2 gene rearrangements in leukaemic B-cells from patients with chronic lymphocytic leukaemia: association with chromosome 6 deletions. <i>British Journal of Haematology</i> , 1994, 86, 291-297.	1.2	7
122	The gene involved in X-linked agammaglobulinaemia is a member of the <i>src</i> family of protein-tyrosine kinases. <i>Nature</i> , 1993, 361, 226-233.	13.7	1,400
123	Specificity and levels of oral and systemic antibodies to <i>Actinobacillus actinomycetemcomitans</i> . <i>Journal of Clinical Periodontology</i> , 1993, 20, 746-751.	2.3	15
124	Analysis of genetic variables in selective human IgG3 deficiency. <i>Tissue Antigens</i> , 1993, 41, 267-268.	1.0	0
125	A 40â€baseâ€pair duplication in the <i>gp91â€i>phox</i></i> gene leading to Xâ€linked chronic granulomatous disease. <i>European Journal of Haematology</i> , 1993, 51, 218-222.	1.1	13
126	Immunoglobulin production in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood mononuclear cells. <i>European Journal of Immunology</i> , 1992, 22, 823-828.	1.6	93

#	ARTICLE	IF	CITATIONS
127	TGF- β 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes. <i>International Immunology</i> , 1991, 3, 1099-1106.	1.8	117
128	Humoral Immunity in scid Mice Reconstituted with Cells from Immunoglobulin-Deficient or Normal Humans. <i>Immunological Reviews</i> , 1991, 124, 113-138.	2.8	38
129	Biological half-life of normal and truncated human IgG3 in scid mice. <i>European Journal of Immunology</i> , 1991, 21, 1319-1322.	1.6	16
130	Different amino acids at position 57 of the HLA-DQ β chain associated with susceptibility and resistance to IgA deficiency. <i>Nature</i> , 1990, 347, 289-290.	13.7	103
131	Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. <i>Immunogenetics</i> , 1990, 31, 285-290.	1.2	82
132	Transcription, translation and secretion of both IgA subclasses in polyclonally activated human lymphocytes. <i>European Journal of Immunology</i> , 1990, 20, 977-982.	1.6	10
133	Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. <i>European Journal of Immunology</i> , 1989, 19, 1311-1315.	1.6	293
134	CORRELATION BETWEEN DEFICIENCY OF IMMUNOGLOBULIN SUBCLASS G3 AND Gm ALLOTYPES. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology</i> , 1986, 94C, 187-191.	0.2	13
135	No Significant Correlation of HLA-B8 and Amount of Antibodies Directed to Acetylcholine Receptor Protein in Patients with Myasthenia Gravis. <i>Tissue Antigens</i> , 1978, 12, 387-395.	1.0	9
136	No Significant Association between HLA and Bell's Palsy. <i>Tissue Antigens</i> , 1978, 12, 404-406.	1.0	8